Post-Exertional Malaise — Hallmark
PEM: Pathognomonic Feature
Post-Exertional Malaise: symptom flare 12–48 hours after physical OR cognitive exertion. Not normal fatigue. Disproportionate, delayed worsening. Unique to ME/CFS in this severity and pattern. The key diagnostic feature. GET (graded exercise) worsens PEM — this is why NICE withdrew GET.
NICE 2021 (GET withdrawal — PEM evidence of harm) · Komaroff & Bateman 2021 NEJM
Post-Viral Trigger (50–80%)
SARS-CoV-2, EBV, enterovirus, HHV-6 — all associated with ME/CFS onset. Long COVID overlap is substantial (30–50% of Long COVID meets ME/CFS criteria). Infection triggers an immune response that doesn't fully resolve. "Viral persistence hypothesis" — viral fragments/reservoirs may drive ongoing immune activation.
Komaroff & Bateman 2021 NEJM (post-COVID ME/CFS) · Naviaux et al. 2016 PNAS (metabolomics)
Mitochondrial Dysfunction
Impaired oxidative phosphorylation. Reduced ATP production per oxygen consumed. Naviaux 2016: metabolomic signature consistent with "cell danger response" — cells switching to hypo-metabolic defensive state. Red blood cell deformability reduced. Ion channel dysfunction proposed.
Naviaux et al. 2016 PNAS (ME/CFS metabolomics) · Younger 2021 (RBC deformability)
NK Cell Dysfunction
Natural killer cells: reduced cytotoxic activity in ME/CFS. Cannot clear viral-infected cells. NK cell phenotype abnormality. Correlates with symptom severity. Cannot defend against viral persistence. This contributes to cycle of ongoing infection → immune activation → PEM.
Brenu et al. 2011 · Fletcher et al. 2010
Neuroinflammation on PET
Microglial activation visible on neuroinflammation PET tracers (TSPO ligands). Brainstem, cingulate, hippocampus predominantly affected. Correlates with cognitive impairment severity. Yoshikawa 2020 (Tokyo study). The "brain fog" has a structural correlate.
Yoshikawa et al. 2020 (brain PET ME/CFS) · SORRY: not yet replicated at scale
Mechanism Unknown — SORRY
Despite multiple hypotheses (autoimmune, mitochondrial, viral persistence, autonomic), the primary mechanism of ME/CFS is unknown. All three may be simultaneously true. The field cannot run trials without a target. Diagnosis is by exclusion. No animal model validated.
SORRY: no confirmed mechanism despite decades of research
Approved Treatment NONE
No Approved Treatment for ME/CFS
SORRY: No pharmacological treatment approved anywhere for ME/CFS as of 2026. Rintatolimod (Ampligen) failed FDA approval. CBT/GET evidence base weakened by PACE trial controversy.
SORRY: rintatolimod failed FDA · GET withdrawn NICE 2021 · CBT re-evaluated
Management (Evidence-Based)
Pacing — Only Evidence-Based Management
Energy management within personal limits (energy envelope). Activity diary, heart rate monitoring, pre-emptive rest before PEM threshold. Avoids PEM triggering. Better quality of life than push/crash cycles. Supported by patient experience + observational data.
Jason et al. 2013 · NICE 2021 (pacing recommended)
⚠ GET WITHDRAWN — Evidence of Harm
Graded Exercise Therapy: gradual increase in activity. Withdrawn from NICE guidelines 2021 after evidence that GET worsened outcomes in PEM patients. PACE trial (2011) controversy: outcomes changed, methodology disputed, patients harmed. Published guidelines caused measurable patient harm.
PACE trial 2011 (controversial) · NICE 2021 (GET withdrawn) · SORRY: guidelines published without adequately understanding PEM
Low-Dose Naltrexone (LDN) Phase 2
Immune modulation via TLR4/microglial pathway. Pain + fatigue modest benefit in Phase 2. Safe profile. Phase 3 not completed. Growing patient-reported evidence. SORRY: mechanism speculative.
Younger et al. Phase 2 data · SORRY: Phase 3 not complete
Biomarker Status LARGEST GAP IN THE FLEET
No Validated Diagnostic Biomarker — THE Biggest Sorry
ME/CFS is diagnosed by clinical criteria (Canadian Consensus Criteria, IOM 2015) after exclusion of other conditions. No blood test, no imaging, no EEG, no biomarker confirms ME/CFS. Patients often go 5–7 years undiagnosed or misdiagnosed. This is the largest diagnostic gap in the entire MEBICAL fleet.
IOM 2015 "Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" · SORRY: diagnosis by exclusion
| NK cell function | Reduced cytotoxic activity. Research biomarker. Not diagnostic. Requires specialist assay. |
| Cytokines (IL-6, TNF-α) | Inconsistently elevated across studies. Cannot diagnose. Nonspecific. |
| Tilt table test | POTS diagnosis (30-50% ME/CFS overlap). Autonomic dysfunction confirmed. Treats the POTS component. |
| Metabolomics | Naviaux 2016 PNAS signature. Cell danger response pattern. Promising but needs replication. Not clinically available. OPEN |
EEG in ME/CFS NON-SPECIFIC
| Alpha intrusion | Alpha waves intrude into theta band. Sherlin 2006. Non-specific. Also seen in fibromyalgia, chronic pain. Not diagnostic for ME/CFS. |
| Alpha power ↓ | Reduced resting alpha power. Non-specific. Fatigue marker generally. |
| Slow waves ↑ | Increased slow wave activity. Correlates with fatigue severity. Not specific. |
| P300 latency ↑ | Delayed cognitive ERP. Brain fog correlate. Not diagnostic. SORRY: all EEG findings in ME/CFS are non-specific, not diagnostic, and poorly replicated across studies. |
SORRY: EEG in ME/CFS has not yielded any diagnostic or pathognomonic finding. All findings are non-specific and consistent with chronic illness/fatigue states generally. MRI neuroinflammation PET is more promising but not yet clinical.
Novel Patterns (8)
PROVENNP-MECFS-001 · PEM (post-exertional malaise) pathognomonic — delayed 12-48hr symptom crash after exertion · unique to ME/CFS severity · the diagnostic keystone
PROVENNP-MECFS-002 · GET withdrawn NICE 2021 — graded exercise caused measurable harm in PEM patients · published guidelines did harm · a cautionary tale for medicine
PROVENNP-MECFS-003 · Long COVID overlap: 30-50% of Long COVID meets ME/CFS criteria · largest real-world experiment in ME/CFS history · forced global attention
OPENNP-MECFS-004 · Naviaux metabolomics 2016: cell danger response signature · mitochondrial defensive state · needs replication · could be first objective biomarker
OPENNP-MECFS-005 · Neuroinflammation PET (microglial TSPO activation) · brainstem + cingulate · brain fog has structural correlate · not yet replicated at scale
OPENNP-MECFS-006 · BC007 (antifibrotic, anti-autoantibody): Phase 2 ongoing · autoantibody hypothesis for ME/CFS subset · could stratify treatment
SORRYNP-MECFS-007 · No diagnostic test exists · diagnosis by exclusion · 5-7yr average to diagnosis · mechanism unknown (autoimmune? mitochondrial? viral persistence? all three?)
SORRYNP-MECFS-008 · Largest biomarker gap in the MEBICAL fleet · no approved treatment · GET caused harm · EEG non-specific · Long COVID relationship unknown · mechanism unknown · no animal model